+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06058663

Phase 1 Study of Yttrium-90 Radioembolization with Tremelimumab and Durvalumab for Advanced Intrahepatic Cholangiocarcinoma Not Eligible for Surgery or Curative Treatment

Led by Mayo Clinic · Updated on 2026-05-13

16

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and side effects of yttrium-90 Y90 radioembolization combined with immunotherapy drugs tremelimumab and durvalumab in patients with intrahepatic cholangiocarcinoma, a rare and aggressive bile duct cancer in the liver. This trial focuses on patients whose cancer is locally advanced, unresectable, or oligo-metastatic and who are not candidates for curative therapy. The study aims to characterize safety, assess treatment response, progression, survival, and explore biomarkers. Participants are assigned to one of two treatment groups. In Cohort I, patients receive transarterial Y90 radioembolization and tremelimumab intravenously on day 1 of cycle 1, followed by durvalumab IV on day 1 of each 28-day cycle, for up to 24 cycles unless disease progresses or toxicity occurs. In Cohort II, patients receive Y90 radioembolization on day 1 of cycle 1, tremelimumab IV on day 14 of cycle 1, and durvalumab IV on day 14 of each cycle, with cycle 1 lasting 42 days and subsequent cycles every 28 days for up to 24 cycles. A dose expansion cohort may be enrolled based on earlier results. During the study, participants undergo mapping angiography, CT, MRI or PETCT scans at screening and on study. Blood samples and tumor biopsies may be collected throughout. After treatment, patients are followed every 3 months for 2 years. Researchers monitor adverse events, treatment response using imaging criteria, progression-free and overall survival, and changes in blood counts and tumor DNA markers to evaluate safety and preliminary efficacy of the combined radioembolization and immunotherapy approach.

CONDITIONS

Brief Title

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Research Team

C

Clinical Trials Referral Office

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here